drugset
drugset / Trial / NCT00946725

To Demonstrate the Relative Bioavailability of Atenolol Tablets, 100 mg

NCT00946725 ↗

Phase 1 Completed 28 enrolled Sandoz
RandomizedCrossoverOpen-labelTreatment

Summary

To demonstrate the relative bioavailability of atenolol tablets, 100 mg.

Timeline

Start
2000-11
Primary completion
2000-11
Completion
2000-11

Drugs

EvaluationDrugModalityDoseRoute
Comparator Atenolol Other / unclassified 100 mg —

Indications

hypertensive disorder intermediate coronary syndrome